Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD
Objective: This study aimed to quantitatively compare the efficacy and safety of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for the treatment of stable chronic obstructive pulmonary disease (COPD), especially in terms of their loss of effica...
Main Authors: | Yiwen Gong, Yinghua Lv, Hongxia Liu, Qingshan Zheng, Lujin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-01-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/17534666211066068 |
Similar Items
-
Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
by: Wei-Chun Huang, et al.
Published: (2022-12-01) -
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01) -
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
by: Vanfleteren L, et al.
Published: (2018-12-01) -
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
by: Luigino Calzetta, et al.
Published: (2017-01-01) -
LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
by: Marc Miravitlles, et al.
Published: (2022-11-01)